Breaking News, Collaborations & Alliances

Orgenesis, SCTbio Partner to Expand POCare Sites in Czech Republic

Leverages SCTbio’s GMP facility for production of lentivirus vectors to support POCare customers.

Orgenesis, a global biotech company working to unlock the full potential of cell and gene therapies (CGT) through its U.S.-based point-of-care (POCare) services subsidiary, Morgenesis LLC, entered into a collaborative agreement with SCTbio, a full-service contract development and manufacturing organization (CDMO) specializing in cell-based therapy and viral vectors. The aim of the collaboration is to open new point-of-care (POCare) sites within the Czech Republic and leverage SCTbio’s GMP fac...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters